Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine

Moderna has submitted the last outstanding data package needed for assessment of the application, containing information that is specific to the manufacturing of the vaccine for the EU market. A meeting to conclude the assessment, if possible, has been made for 6 Jan 2021.

Source:

European Medicines Agency